A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathway

doi:10.1016/S2095-4964(16)60251-0

Abstract

Objective

Homeopathic nosodes have seldom been scientifically validated for their anticancer effects. This study was conducted to examine if a recently developed hepatitis C nosode has demonstrable anticancer potential in cancer cells in vitro.

Methods

Anticancer effects of Hepatitis C 30C (Hep C 30), if any, were initially tested on three cancer cell lines, HepG2 (liver cancer), MCF-7 (breast cancer) and A549 (lung cancer) and one normal liver cell line WRL-68 cells and subsequently a more thorough study using further scientific protocols was undertaken on HepG2 cells (against WRL-68 cells as the normal control) as HepG2 cells showed better anticancer response than the other two. Three doses, one at 50% lethal dose (LD50) and the other two below LD50, were used on HepG2 cells subsequently. Protocols like apoptosis induction and its possible signaling mechanism were deployed using immunoblots of relevant signal proteins and confocal microscopy, with particular reference to telomerase and topoisomerase II (Top II) activities, two strong cancer biomarkers for their direct relationship with divisional activities of cells and DNAs.

Results

Hep C 30 induced apoptosis, caused distorted cell morphology typical of apoptotic cells, increased reactive oxygen species generation and produced increased DNA nicks. Further it enhanced pro-apototic signal proteins like Bax, cytochrome c and inhibited anti-apoptotic signal proteins, Bcl-2, cytochrome c and caspase-3, changed mitochondrial membrane potential and caused externalization of phosphatidylserine. The drug also decreased expression of two cancer biomarkers, Top II and telomerase, consistent with its anticancer effect.

Conclusion

Hep C 30 has demonstrable anticancer effects against liver cancer cells in vitro.

Key words: Formularies, Homeopathic, Antineoplastic agents, Telomerase, DNA topoisomerases, Type II, Membrane potential, Mitochondrial

Jesmin Mondal, Jayeeta Das, Rajesh Shah, Anisur Rahman Khuda-Bukhsh. A homeopathic nosode, Hepatitis C 30 demonstrates anticancer effect against liver cancer cells in vitro by modulating telomerase and topoisomerase II activities as also by promoting apoptosis via intrinsic mitochondrial pathway. Journal of Integrative Medicine, 2016, 14(3): 209-218.

/ / Recommend

Add to citation manager EndNote| Reference Manager|ProCite|BibTeX|RefWorks

URL: http://www.jcimjournal.com/EN/10.1016/S2095-4964(16)60251-0

http://www.jcimjournal.com/EN/Y2016/V14/I3/209

trendmd

References

1 Shah R.Hepatitis C Nosode: the preparation and homeopathic pathogenetic trial. Homeopathy. 2013; 102(3): 207-214.
2 Shah R.Scientific method of preparing homoeopathic nosodes. Indian [J] Res Homeopath. 2014; 8(3): 166-173.
3 Shah R.HIV Nosode: The homeopathic pathogenetic trial. Forsch Komplementmed. 2015; 22(3): 156-162.
4 Shah R.A clinical evaluation of a Hepatitis C Nosode in the treatment of hepatitis C. [J] Altern Complement Med. 2016; 22(3): 197-203.
5 Mondal J, Samadder A, Khuda-Bukhsh AR.Psorinum 6× triggers apoptosis signals in human lung cancer cells. [J] Integr Med. 2016; 14(2): 143-153.
6 Alter MJ.Epidemiology of hepatitis C virus infection. World [J] Gastroenterol. 2007; 13(17): 2436-2441.
7 Mosmann T.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. [J] Immunol Methods. 1983; 65(1-2): 55-63.
8 Matassov D, Kagan T, Leblanc J, Sikorska M, Zakeri Z.Measurement of apoptosis by DNA fragmentation. Methods Mol Biol. 2004; 282: 1-17.
9 Khuda-Bukhsh AR.Potentized homeopathic drugs act through regulation of gene expression: a hypothesis to explain their mechanism and pathways of action in vivo. Complement Ther Med. 1997; 5(1): 43-46.
10 Khuda-Bukhsh AR.Current trends in ultra-high dilution research with particular reference to gene regulatory hypothesis: review article. Nucleus. 2014; 57(1): 3-17.
11 Gerl R, Vaux DL.Apoptosis in the development and treatment of cancer. Carcinogenesis. 2005; 26(2): 263-270.
12 Kaufmann SH, Vaux DL.Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 2003; 22(47): 7414-7430.
13 Krysko DV, Vanden Berghe T, Parthoens E, D’Herde K, Vandenabeele P. Methods for distinguishing apoptotic from necrotic cells and measuring their clearance. Methods Enzymol. 2008; 442: 307-341.
14 Jackson SP.Sensing and repairing DNA double-strand breaks. Carcinogenesis. 2002; 23(5): 687-696.
15 Abbotts R, Thompson N, Madhusudan S.DNA repair in cancer: emerging targets for personalized therapy. Cancer Manag Res. 2014; 6: 77-92.
16 Lakin ND, Jackson SP.Regulation of p53 in response to DNA damage. Oncogene. 1999; 18(53): 7644-7655.
17 Christmann M, Kaina B.Transcriptional regulation of human DNA repair genes following genotoxic stress: trigger mechanisms, inducible responses and genotoxic adaptation. Nucleic Acids Res. 2013; 41(18): 8403-8420.
18 Wang JC.Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002; 3(6): 430-440.
19 Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, Durkacz BW. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood. 2004; 103(12): 4659-4665.
20 Thakur DS.Topoisomerrase II inhibitors in cancer treatment. Int [J] Pharm Sci Nanotechnol. 2011; 3(4): 1173-1181.
21 Trachootham D, Alexandre J, Huang P.Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009; 8(7): 579-591.
22 Liu Y, Jiao R, Ma ZG, Liu W, Wu QQ, Yang Z, Li FF, Yuan Y, Bian ZY, Tang QZ.Sanguinarine inhibits angiotensin II-induced apoptosis in H9c2 cardiac cells via restoring reactive oxygen species-mediated decreases in the mitochondrial membrane potential. Mol Med Rep. 2015; 12(3): 3400-3408.
23 Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW.Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266(5193): 2011-2015.
24 Shay JW, Zou Y, Hiyama E, Wright WE.Telomerase and cancer. Hum Mol Genet. 2001; 10(7): 677-685.
25 Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014; 2014: 150845.
26 Chikramane PS, Kalita D, Suresh AK, Kane SG, Bellare JR.Why extreme dilutions reach non-zero asymptotes: a nanoparticulate hypothesis based on froth flotation. Langmuir. 2012; 28(45): 15864-15875.
27 Rajendran ES.Nanodynamics. Cochin: Mohna Publications. 2015: 170-178.
28 Eskinazi D.Homeopathy re-revisited: is homeopathy compatible with biomedical observations? Arch Intern Med. 1999; 159(17): 1981-1987.
29 Bell IR, Schwartz GE, Boyer NN, Koithan M, Brooks AJ.Advances in integrative nanomedicine for improving infectious disease treatment in public health. Eur [J] Integr Med. 2013; 5(2): 126-140.
30 Bell IR, Sarter B, Koithan M, Banerji P, Banerji P, Jain S, Ives J.Integrative nanomedicine: treating cancer with nanoscale natural products. Glob Adv Health Med. 2014; 3(1): 36-53.
31 Bell IR, Ives JA, Jonas WB.Nonlinear effects of nanoparticles: biological variability from hormetic doses, small particle sizes, and dynamic adaptive interactions. Dose Response. 2013; 12(2): 202-232.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 10

[1]	Jin-rong Fu. Establishment of multivariate diagnosis and treatment system of modern gynecology of traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 22-24
[2]	Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[3]	Zhi-chun Jin. Problems in establishing clinical guideline for integrated traditional Chinese and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 5-8
[4]	SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[5]	Min Cheng, Qiong Feng, Shu-wen Qian, Hui Gao, Cui-qing Zhu. Preliminary assay of p-amyloid binding elements in heart-beneficial recipe. Journal of Chinese Integrative Medicine, 2008, 6(1): 68-72
[6]	Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97
[7]	Jing-yuan Mao, Chang-xiao Liu, Heng-he Wang, Guang-li Wei , Zhen-peng Zhang, Jie Xing, Wang Xian liang , Ying-fei Bi . Effects of Shenmai Injection on serum concentration and pharmacokinetics of digoxin in dogs with heart failure. Journal of Chinese Integrative Medicine, 2010, 8(11): 1070-1074
[8]	Zhi-mei Wang, Bin Zhang. A study on translation of ellipses in Huangdi Neijing from perspective of hermeneutic theory. Journal of Chinese Integrative Medicine, 2010, 8(11): 1097-1100
[9]	Gui Yu, Jie Wang. Thinking on building the network cardiovasology of Chinese medicine. Journal of Chinese Integrative Medicine, 2012, 10(11): 1206-1210
[10]	Pedro Saganha João, Doenitz Christoph, Greten Tobias, Efferth Thomas, J. Greten Henry. Qigong therapy for physiotherapists suffering from burnout: a preliminary study. Journal of Chinese Integrative Medicine, 2012, 10(11): 1233-1239